The evidence.
Every formula in the VEDASCO® collection is built on a single standard: the clinical evidence had to exist first. We don't formulate to trend. We formulate to the trial.
01
Our evidence standard.
Human RCT data only
We require randomised controlled trial evidence in humans for every dose decision. Animal models and in vitro studies are read for mechanism, but do not drive formulation.
Pre-registered where available
We prioritise studies with pre-registered primary outcomes. This reduces selection bias in the evidence we rely on.
Appropriate comparator
We look for placebo-controlled or active-comparator designs. Open-label and case reports are read for signal, never for dose justification.
Reproducibility
A single positive study is not sufficient. We look for corroboration across independent research groups before including an ingredient.
02
Our regulatory standard.
EU GMP Manufacture
Every VEDASCO® formula is manufactured under EU Good Manufacturing Practice. GMP certification requires documented procedures, qualified personnel, validated equipment, and full batch traceability.
HPLC Batch Testing
High-Performance Liquid Chromatography is used to verify active marker compound concentrations in every production batch. No batch leaves without a passing HPLC certificate of analysis.
ISO 17025 Independent Laboratory
Third-party verification by an ISO 17025 accredited laboratory. ISO 17025 is the international standard for testing and calibration laboratories — the same standard used in pharmaceutical quality control.
EMA HMPC & EFSA Regulatory Alignment
Ingredients are selected within the regulatory framework of the European Medicines Agency Herbal Committee (EMA HMPC) monographs and EFSA authorised health claims. We do not use Novel Foods without explicit EU authorisation.
03
Clinical validation.
Outcome statements from the randomised controlled trials that form the evidential basis for each formula. Full clinical references are available to registered healthcare professionals through our Practitioner Portal.
Significant reduction in perceived stress score vs. placebo in a 12-week randomised controlled trial in adults with stress-related fatigue.
Clinical reference available to practitioners →Significant improvement in mood outcomes at 6 weeks, validated against an active comparator, in a double-blind randomised trial.
Clinical reference available to practitioners →Significant improvement in sperm progressive motility vs. placebo in a 6-month double-blind randomised trial in men with idiopathic asthenozoospermia.
Clinical reference available to practitioners →Significant improvement in erectile function score vs. placebo across a systematic review of multiple randomised controlled trials.
Clinical reference available to practitioners →Significant improvement in subjective sleep quality across a systematic review and meta-analysis of 16 randomised controlled trials.
Clinical reference available to practitioners →Significant improvement in sleep quality score (PSQI) and reduction in stress-related symptoms in a 4-week randomised controlled trial.
Clinical reference available to practitioners →Patients reporting PMS symptom improvement versus placebo at 3 menstrual cycles in a double-blind randomised controlled trial.
Clinical reference available to practitioners →04
Practitioner access.
Healthcare professionals can request full clinical references, certificates of analysis for current batches, and wholesale professional pricing through the VEDASCO® Practitioner Portal.
Request practitioner access →